CHROMATOGRAPHIC METHOD OF SEPARATION OF RADIONUCLIDE LUTETIUM-177, CARRIER FREE FROM MACRO-QUANTITIES OF YTTERBIUM
DOI:
https://doi.org/10.17605/OSF.IO/AG2D8Keywords:
lutetium, ytterbium, carrier free, half-life, isotop, separation, radionuclide, Chromatographic method, irradiating, thermal neutron, nuclear reactor, nuclear reaction, ion-exchange resin, chromatographic column, HPLC, gradient.Abstract
Currently, promising direction of development of modern oncology is a radionuclide therapy using radiopharmaceuticals sighting direction, ie the targeted effect on tumor tissue. For this purpose, suitable radionuclide 177Lu, possessing optimal nuclear-physical characteristics with an average half-life (T1/2 = 6,7 days); acceptable energy β-particles (maximum 0,5 MeV), which allows to destroy small tumors and metastasis without affecting the healthy tissues; concomitant soft γ-radiation with sufficient energy for imaging. Targeted exposure helps to get rid of neuroendocrine tumors, thyroid cancers, some types of brain cancer, and prostate cancer, and so on.
Downloads
References
SNMMI/NCI Third Targeted Radionuclide Therapy Conference 2019 Monday, December 16, 2019, National Cancer Institute – Shady Grove, Maryland
Louise Emmett, Kathy Willowson, John Violet, Jane Shin, Ashley Blanksby, Jonathan Lee. Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. – J. Med. Radiat. Sci. 2017, 64(1), Р. 52-60.
Кодина Г.Е., Красикова Р.Н. Методы получения радиофар м ацев тиче ских препара т ов и радио -нуклидных генераторов для ядерной медицины. М., 2014. С. 60.
В.А. Тарасов, Е.Г. Романов, Р.А. Кузнецов. СРАВНИТЕЛЬНЫЙ АНАЛИЗ СХЕМ РЕАКТОРНОЙ НАРАБОТКИ ЛЮТЕЦИЯ-177. Известия Самарского научного центра Российской академии наук, 2013, т. 15, №4(5), С. 1084-1090.
Отчет НИР Института Ядерной Физики Академии Наук Республики Узбекистан. № Гос рег. 01.2000.09698, Ташкент 2002, 40 с.
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.















